Parkman Healthcare Partners LLC Has $6.47 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Parkman Healthcare Partners LLC lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 20.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 605,318 shares of the biopharmaceutical company's stock after purchasing an additional 102,855 shares during the quarter. Parkman Healthcare Partners LLC owned approximately 0.20% of Amicus Therapeutics worth $6,465,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in Amicus Therapeutics during the third quarter worth $55,000. Erste Asset Management GmbH acquired a new position in shares of Amicus Therapeutics during the 3rd quarter valued at about $1,251,000. Edgestream Partners L.P. grew its holdings in Amicus Therapeutics by 184.6% during the third quarter. Edgestream Partners L.P. now owns 258,605 shares of the biopharmaceutical company's stock valued at $2,762,000 after purchasing an additional 167,735 shares during the last quarter. PDT Partners LLC acquired a new position in Amicus Therapeutics during the third quarter valued at approximately $2,702,000. Finally, Vinva Investment Management Ltd acquired a new position in Amicus Therapeutics in the 3rd quarter valued at $143,000.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Jefferies Financial Group initiated coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They issued a "buy" rating and a $18.00 target price on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Bank of America raised their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Thursday, October 17th. Guggenheim upped their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Finally, StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.63.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,884,273.08. This trade represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 30,401 shares of company stock worth $339,363 over the last quarter. 2.20% of the stock is currently owned by company insiders.

Amicus Therapeutics Trading Up 0.7 %

Shares of FOLD stock traded up $0.07 during trading hours on Wednesday, reaching $9.86. The company had a trading volume of 1,685,165 shares, compared to its average volume of 2,684,374. Amicus Therapeutics, Inc. has a 1-year low of $9.02 and a 1-year high of $14.57. The company has a 50 day moving average of $10.65 and a 200 day moving average of $10.61. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of -28.79 and a beta of 0.60.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.